GLP-1

#Diabetes #Eli Lilly #GLP-1 #Phase III trial

Lilly’s oral GLP-1 first to complete a Phase III trial

Eli Lilly has announced positive topline Phase III results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycaemic control with diet and exercise alone.   Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor… Read More

#Editor's Choice #News

Obese man measures his waist
#GLP-1 #MetaVia #Obesity #Phase I trial #Weight loss

New obesity drug shows superior tolerability to GLP-1 agonists

MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity.  DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor… Read More

#Editor's Choice #News

Pfizer, New York
#Clinical trial #GLP-1 #Pfizer #Weight loss

Pfizer discontinues oral GLP-1 receptor agonist danuglipron

Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury.  Danuglipron (PF-06882961) was being investigated for chronic weight management.  The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose… Read More

#Business & Investment #News #Trending News

Heart monitor
#Cardiovascular disease #Chronic kidney disease (CKD) #Diabetes #GLP-1 #Novo Nordisk #Weight loss

Oral semaglutide reduces risk of cardiovascular events

The results of the SOUL cardiovascular outcomes trial have demonstrated that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).   The new data were featured during a late-breaking clinical… Read More

#News

#GLP-1 #Weight loss #Women's health

New DDW Highlights podcast: 31 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Weight loss drugs have been… Read More

#News

#GLP-1 #Obesity #Weight loss #Women's health

This week in drug discovery (24-28 March) 

News round-up for 24-28 March by DDW Senior Digital Content Editor Diana Spencer. Weight loss drugs have been making the news this week. As we come to the end of Women’s History Month, two of the reported studies focus on women’s health, specifically the role of weight loss… Read More

#News

#Cardiovascular disease #Closed Loop Medicine #GLP-1 #US patent

Closed Loop Medicine secures US patents for GLP-1 therapies

Closed Loop Medicine has been granted US patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.  The company currently holds over 65 filings across 16 patent families.   In the rapidly-established GLP-1 market, the company’s IP covers dose optimisation according to patient-specific… Read More

#Business & Investment #News

Patient injects Ozempic
#Gender #GLP-1 #Obesity #Olio Labs #Preclinical investigations #Weight loss

Study reveals insights into GLP-1 drug effectiveness across sexes 

A new study has uncovered fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic and Zepbound.  Founded by leading neuroscientists and computational biologists in 2023, Olio Labs uses a novel… Read More

#News

Endometriosis
#Endometriosis #GLP-1 #Weight loss

Mounjaro’s role in managing endometriosis

Endometriosis is a chronic and often debilitating condition affecting one in 10 women in the UK. Weight management and metabolic health play an essential role in symptom control. The weight loss drug Mounjaro (tirzepatide) and its effects on appetite regulation, insulin sensitivity, and weight loss, could be an unexpected tool… Read More

#News

Woman standing on scales
#Diabetes #GLP-1 #Obesity #Phase I trial #Vivani Medical #Weight loss

GLP-1 implant NPM-115 enters clinical trials for obesity

Vivani Medical has announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial.   The company hopes to address one of healthcare’s most pressing challenges: medication adherence in metabolic diseases including chronic weight management and type 2 diabetes.   Vivani also announced… Read More

#News

#GLP-1 #Market reporting #Novo Nordisk #Obesity #Scandinavia #Weight loss

What effect have weight loss drugs had on the Scandinavian economy?

In less than a decade GLP-1 receptor agonists have transformed the treatment of obesity and made Novo Nordisk Europe’s most valuable company. Diana Spencer explores the current impact and potential future for these drugs. Originally designed in Scandinavia as a maintenance therapy for type 2 diabetes, GLP-1 receptor agonists are… Read More

#Exclusive Content #Market Reports #Trends & Analysis

Scales showing a comparison between Mounjaro and Ozempic
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

New data show Zepbound/Mounjaro superior to Wegovy for weight loss

Eli Lilly’s Zepbound/Mounjaro (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide, also known as Ozempic), according to topline results from the SURMOUNT-5 Phase IIIb clinical trial.  On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. … Read More

#News #Trending News

Human liver
#Cardiometabolic diseases #GLP-1 #Monoclonal antibodies #Obesity #Tiziana Life Sciences

Ozempic and antibody combination restores liver homeostasis

New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy). The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO). Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

New DDW Highlights episode: 15 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

This week in drug discovery (7-11 Oct) 

News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More

#News

#Antag Therapeutics #FDA #GLP-1 #Obesity #Phase I trial #Weight loss

FDA clears GIP receptor agonist trial in obese subjects

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and… Read More

#News #Regulatory